2019-05-06T16:09:00-05:00 2018-06-30 KPMG LLP 345 Park Avenue NEW YORK NY 101540102 990 2017-07-01 954335088 Lymphoma Research Foundation % CAROL FLORES LYMP 2123492910 WALL ST PLAZA 88 PINE STREET Suite New York NY 10005 MEGHAN GUTIERREZ CEO 2123492910 2019-05-06 true Nicole Fitzmaurice P01491005 2127589700 2019-04-15 167.68.102.5 13407320191265000008 2019-05-06 P BE98CA47A8C9128CF71C54AFD7DACECDEDE7F2F8 F7E791049FCEE4943A341CCA4F642AE72B60D2A0 2017 2019-02-21 02:37:17Z MEGHAN GUTIERREZ WALL ST PLAZA 88 PINE STE 2400 New York NY 10005 10544009 false X www.lymphoma.org X 2001 NY THE LYMPHOMA RESEARCH FOUNDATION'S MISSION IS TO ERADICATE LYMPHOMA AND SERVE THOSE TOUCHED BY THIS DISEASE. FOR MORE INFORMATION, SEE SCHEDULE O. 23 23 37 10000 0 12321 7784192 7229093 2321617 2791017 95587 118925 -148869 -118198 10052527 10020837 1920900 1251239 0 0 3171887 3261065 0 0 2027419 3691481 3949008 8784268 8461312 1268259 1559525 12745237 13738328 3908792 3380869 8836445 10357459 X The Lymphoma Research Foundation's (LRF) Mission is to eradicate Lymphoma and serve those touched by this disease. SEE SCHEDULE O. false false 2943183 7200 EDUCATIONAL PROGRAMS AND PATIENT SERVICES: LRF PROVIDES A COMPREHENSIVE SERIES OF PROGRAMS AND SERVICES FOR THE LYMPHOMA COMMUNITY INCLUDING, BUT NOT LIMITED TO, CONTINUING MEDICAL EDUCATION, CLINICAL TRIALS INFORMATION SERVICES, DISEASE SPECIFIC PUBLICATIONS AND WEBSITES, IN-PERSON PATIENT WORKSHOPS AND EDUCATIONAL FORUMS, LYMPHOMA HELPLINE, ONLINE SERVICES, PATIENT AID GRANTS, TELECONFERENCES AND WEBCASTS/PODCASTS, WITH A VOLUNTEER COMMUNITY NETWORK. 2213436 1244039 RESEARCH: LRF REMAINS DEDICATED TO FINDING A CURE FOR LYMPHOMA THROUGH AN AGRESSIVELY-FUNDED RESEARCH PROGRAM. LRF SUPPORTS INNOVATIVE RESEARCH AND TRAINING FOR EARLY CAREER SCIENTISTS THROUGH ITS YOUNG INVESTIGATOR GRANTS. See SCHEDULE O. 783633 COMMUNICATION AND ADVOCACY: LRF REPRESENTS THE NEEDS OF PEOPLE WITH LYMPHOMA BY SUPPORTING PUBLIC POLICIES WHICH SEEK TO INCREASE FEDERAL FUNDING FOR LYMPHOMA RESEARCH AND ENSURE ACCESS TO HIGH QUALITY CANCER CARE. THE LRF ADVOCACY PROGRAM PROVIDES VOLUNTEER ADVOCATES WITH THE RESOURCES NECESSARY TO GARNER ATTENTION AND SUPPORT FOR THOSE PUBLIC POLICIES MOST IMPORTANT TO THE LYMPHOMA COMMUNITY, THROUGH STRATEGIC COMMUNICATIONS, LRF SEEKS TO RAISE AWARENESS OF LYMPHOMA AND HAVE DISEASE INFORMATION AT THE FINGERTIPS OF MORE PEOPLE THAN EVER BEFORE. 5940252 true true false true false false false false false false true false false false false true true false false false false false false false true false false true true true false false false false false false false false true false false false false true true true false false true 57 0 true 37 true false false false false false true true false false false false X 23 23 true false false false false false false true true false true true true true true true true true true false true true AL AR CA FL GA HI IL KS KY MD MA MI MN MS MO NV NH NJ NM NY NC OR PA RI SC TN UT VA WV WI X X CAROL FLORES 2123492910 WALL ST PLAZA 88 PINE STE 2400 NEW YORK NY 10005 X MICHAEL AKINYELE BOARD MEMBER 1.0 0.0 X 0 0 0 JOSEPH R BERTINO MD BOARD MEMBER-FOUNDER SCI BOARD 1.0 0.0 X 0 0 0 ERIC COHEN BOARD MEMBER 1.0 0.0 X 0 0 0 DR MORTON COLEMAN BOARD MEMBER - CHAIR MAB 1.0 0.0 X 0 0 0 TOM CONDON BOARD MEMBER 1.0 0.0 X 0 0 0 ERROL M COOK BOARD MEMBER 1.0 0.0 X 0 0 0 KEVIN FENNESSEY BOARD MEMBER 1.0 0.0 X 0 0 0 JOSEPH M FERRARO BOARD MEMBER 1.0 0.0 X 0 0 0 THOMAS E GOLDSTONE BOARD MEMBER 1.0 0.0 X 0 0 0 THOMAS HABERMANN BOARD MEM.CHAIR SAB BEG 7/1/17 3.0 0.0 X 0 0 0 KEITH HOOGLAND BOARD MEMBER 1.0 0.0 X 0 0 0 LEIGH OLSON SECRETARY 1.0 0.0 X X 0 0 0 ROBERT MCAULEY BOARD MEMBER 1.0 0.0 X 0 0 0 LANCE MEYEROWICH BOARD MEMBER 1.0 0.0 X 0 0 0 JOHN A NELSON BOARD MEMBER 1.0 0.0 X 0 0 0 STEVEN J PRINCE TREASURER/PAST CHAIR 2.0 0.0 X X 0 0 0 DONNA REINBOLT BOARD MEMBER 1.0 0.0 X 0 0 0 STEVEN E ROSEN BOARD MEMBER 1.0 0.0 X 0 0 0 SHERI ROSENFELD BOARD MEMBER 1.0 0.0 X 0 0 0 MICHAEL WERNER CHAIRMAN 5.0 0.0 X X 0 0 0 ROBERT WERNER BOARD MEMBER 1.0 0.0 X 0 0 0 BRUCE YABLON BOARD MEMBER 1.0 0.0 X 0 0 0 JOHN LEONARD MD BOARD MEMBER BEG 9/28/17 1.0 0.0 X 0 0 0 MEGHAN GUTIERREZ CHIEF EXECUTIVE OFFICER 35.0 0.0 X 250224 0 12365 LISA WEGWEISER-VOGELL CFO & COO END: 2/8/18 35.0 0.0 X 204699 0 42756 CAROLINA FLORES SENIOR DIRECTOR OF FINANCE 35.0 0.0 X 113223 0 45274 DENNIS CHILLEMI SENIOR DIRECTOR OF DEVELOPMENT 35.0 0.0 X 141514 0 120 PEGGY ANN TORNEY CHIEF STRATEGY,COM.&ENGA. OFF. 35.0 0.0 X 134613 0 19703 844273 0 120218 5 false true false Marriott Business Services PO Box 402642 ATLANTA GA 30384 VENUE & CATERING 401309 Blackbaud Inc 2000 Daniel Drive CHARLESTON SC 29492 CONSULT/SYSTEM MAINT 360617 AOIC LLC One East Uwchlan Suite 408 EXTON PA 19341 CONSULTING/PRINTING 242625 Imedex LLC Dept 111074 PO Box 150503 HARTFORD CT 06115 VENUE & CATERING 133877 The Westin Chicago River North 320 N Dearborn Avenue CHICAGO IL 60654 VENUE & CATERING 116919 5 46354 2716752 4465987 214290 7229093 EDUCATION PROGRAMS & PATIENT SERVICES 900099 2791017 2791017 2791017 116297 116297 0 0 0 0 0 216918 214290 2628 2628 2628 175495 2716752 308882 -133387 -133387 0 0 0 0 0 0 OTHER ACTIVITES 15189 15189 15189 10020837 2791017 727 1244039 1244039 7200 7200 0 0 761609 420411 67185 274013 0 1907141 1054063 168448 684630 64969 36112 5771 23086 231727 123225 19692 88810 295619 163386 26111 106122 0 16349 9036 1444 5869 58560 58560 0 0 0 366086 270069 5955 90062 133898 89544 635 43719 369744 252641 5807 111296 76542 59569 3203 13770 0 428616 236893 37857 153866 483173 394592 5306 83275 0 1300972 1258151 10875 31946 0 0 159210 87994 14062 57154 26018 14380 2298 9340 PROCESSSING FEES AND OTHER 211453 58123 35465 117865 REPAIRS AND MAINTENANCE 134300 73329 11899 49072 LICENSE AND PERMITS 5342 0 1317 4025 MISCELLANEOUS AND OTHER EXPENS 178745 87495 11751 79499 8461312 5940252 493641 2027419 1280317 1241981 9767253 10036255 451200 300000 25838 1066035 0 0 0 0 70482 100150 0 0 419543 291853 785288 195120 637083 590168 93521 111886 0 0 0 0 0 0 0 0 12745237 13738328 789122 532577 2984670 2730792 135000 117500 0 0 0 0 0 0 0 0 0 0 0 0 3908792 3380869 X 3171611 3294149 5664834 7063310 0 0 8836445 10357459 12745237 13738328 1559525 -38511 X false true X true false X 6841488 6344995 6847149 7784192 7229093 35046917 0 0 6841488 6344995 6847149 7784192 7229093 35046917 8983409 26063508 48325 43425 57884 95465 116297 361396 0 3094 18320 5680 18492 15189 60775 35469088 13570285 0.73482 0.61190 X false true false false false false true 32743 false true 74979 107722 false Schedule C, Part II-B, Line 1 Other lobbying activities: contact with legislators, their staff, government officials, legislative bodies, and associated grassroots activities to present issues of concern related to lymphoma. 112190 13967 98223 0 668174 178628 489546 4925 2526 2399 590168 0 0 X 11396965 -38511 1105757 1067246 10329719 -308882 -308882 10020837 9905619 1105757 338550 1444307 8461312 8461312 Schedule D, Part X, Line 2: LRF recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Income generated from activities unrelated to the Foundation's exempt purpose is subject to tax under Internal Revenue Code Section 511. The Foundation did not recognize any unrelated business income tax liability in 2017 but did so in 2018 due to tax reform. Schedule D, Part XI, Line 4b: Expenses related to fundraising events are reported in Part VIII, Statement of Revenue, Line 8B, together with fundraising events revenue. Schedule D, Part XII, Line 2d: Expenses related to fundraising events are reported in Part VIII, Statement of Revenue, Line 8B, together with fundraising event revenue. LRF's audited financial statements report income and expenses on a consolidated basis with a relative entity, LRF Research Inc. This entity's only activity for the year includes expenses of $29,668, which have been reversed out for separate tax reporting. Active Lifestyl 1386037 1386037 32709 34494 5704 5651 2017 Annual Gal 793150 706900 86250 928 97527 5612 6 713060 623815 89245 16463 101300 360 8135 2892247 2716752 175495 50100 233321 6064 19398 308883 -133388 true DUKE UNIVERSITY MEDICAL CENTER 101 Science Drive Durham NC 27705 560532129 501(c)(3) 250000 Cash Genome predictors of response in mantle cell lymphoma. HLEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE 12902 Magnolia Dr TAMPA FL 33612 592451713 501(C)(3) 250000 Cash New Therapeutic Vulnerabilities for Ibrutinib Resistance Mantle Cell Lymphoma (MCL). MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT ST BOSTON MA 02114 BOSTON MA 02114 046123511 501(C)(3) 225000 CASH Eradicating minimum residual disease CHILDREN RESEARCH INSTITUTE 111 Michigan Ave WASHINGTON DC 20010 521654453 501(c)(3) 225000 CASH Developing syngergistic immunetherapies for high risk Hodgkin Lymphoma. DANA-FARBER CANCER INSTITUTE 450 Brookline Avenue BOSTON MA 02215 042263040 501(c)(3) 105000 CASH DECIPHERING THE ROLE FELLOWSHIP AWARD DUKE UNIVERSITY 101 SCIENCE DRIVE DURHAM NC 27705 560532129 501(c)(3) 105000 CASH THE TUMOR SUPPRESSIVE FELLOWSHIP AWARD COLUMBIA UNIVERSITY MEDICAL CENTER 161 Fort Washington HIP NEW YORK NY 10032 135598093 501(c)(3) 100000 CASH Cancer care delivery and survival disparities in AYAs with Hodgkin lymphoma. UNIVERSITY OF WASHINGTON 825 Eastlake Ave E SEATTLE WA 98109 916001537 501(c)(3) 10000 CASH A Pilot Trial of TGR-1202 and Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma. MAYO CLINIC 200 First St SW ROCHESTER MN 55905 416011702 501(c)(3) 10000 CASH Impact of Health Behaviors on Outcomes in Lymphoma Survivors: A Prospective Database and Pilot Study. UNIVERSITY OF ROCHESTER 518 Hylan Bldg Box 270140 ROCHESTER NY 14627 160743209 STATE ENTITY 10000 CASH Restoring mutant P53 function in B-cell lymphomas. BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA HOUSTON TX 77030 741613878 CORPORATION 10000 CASH THE ROLE OF BIOLOGY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 101 THE CITY DR S ORANGE CA 92848 952226106 501(c)(3) 10000 CASH Randomized phase II study of R-miniCHOP +/- oral azacytidine in elderly patients with DLBCL. DANA-FARBER CANCER INSTITUTE 450 Brookline Avenue BOSTON MA 02215 042263040 501(c)(3) 10000 CASH A phase I/II trial of azacitidine plus venetoclax for the treatment of diffuse large B-cell Lymphoma. EMORY UNIVERSITY 1365 Clifton Rd NE ATLANTA GA 30322 580566256 501(c)(3) 10000 CASH Efficacy of bendamustine-obinutuzumab-venetoclax induction in untreated mantle cell lymphoma. HEALTH RESEARCH INCORPORATED ROSWELL PARK ELM CARLTON ST BUFFALO NY 14263 161552370 501(c)(3) 10000 CASH Phase I/II Study of Pevonedistat with Rituximab and Ibrutinib for Relapsed/Refractory MCL. 14 1 PATIENT AID GRANTS 72 7200 CASH Schedule I, Part I, Line 2 LRF'S Scientific Advisory Board (SAB) reviews all grant proposals and recommends to LRF's Board of Directors which grants to fund. The Board then approves the grants to be funded based upon the SAB's recommendations. Once a grant is approved and accepted by the grantee, the grantee will begin to receive installments based upon the payment schedule as dictated in the contract. The SAB and LRF's Research Department annually review each grantee's progress against deliverables and approves the continuation of grant payments. Schedule I, Part III LRF provides financial assistance to Lymphoma patients who struggle to pay for expenses related to their lymphoma treatments, such as medical bills and transportation costs. Our patient services team reviews the applications and submits them to the Chief Strategy, Communications, and Engagement Officer for payment approval. X X X false false false false false false false true false MEGHAN GUTIERREZ CHIEF EXECUTIVE OFFICER 235224 0 15000 0 0 0 11354 0 1011 0 262589 0 0 0 LISA WEGWEISER-VOGELL CFO & COO END: 2/8/18 204699 0 0 0 0 0 10217 0 32539 0 247455 0 0 0 PEGGY ANN TORNEY CHIEF STRATEGY,COM.&ENGA. OFF. 134613 0 0 0 0 0 6667 0 13036 0 154316 0 0 0 CAROLINA FLORES SENIOR DIRECTOR OF FINANCE 113223 0 0 0 0 0 6148 0 39126 0 158497 0 0 0 Schedule J, Part I line 7 Meghan Gutierrez, CEO, received discretionary, non-fixed bonus payment in calendar year 2017, which is approved by the chairman of the organization. X 22 214290 Market Price false true false FORM 990, PART I, LINE 1 LRF IS THE NATION'S LARGEST NON-PROFIT ORGANIZATION DEVOTED TO FUNDING INNOVATIVE RESEARCH AND SERVING THE LYMPHOMA COMMUNITY THROUGH A COMPREHENSIVE SERIES OF EDUCATION PROGRAMS, OUTREACH INITIATIVES, AND PATIENT SERVICES. LRF INVESTS MILLIONS OF DOLLARS EVERY YEAR TO COMBAT LYMPHOMA AND ASSIST THOSE WHOSE LIVES HAVE BEEN AFFECTED BY A LYMPHOMA DIAGNOSIS. LRF IS SUPPORTED BY MORE THAN 10,000 VOLUNTEERS WHO CONTRIBUTE THEIR TIME AND TALENTS TO FURTHER THE LRF MISSION AND SERVE THEIR LOCAL COMMUNITIES. LRF HAS EARNED THE TRUST OF INDIVIDUALS, PRIVATE FOUNDATIONS, PUBLIC COMPANIES, AND ORGANIZATIONS THAT FUND ITS WORK BY DEMONSTRATING A HISTORY OF CAREFUL AND PROVEN FINANCIAL STEWARDSHIP. FORM 990, PART III, LINE 1 - ORGANIZATION'S MISSION LRF IS DEDICATED TO IDENTIFYNG A CURE THROUGH AN AGGRESIVELY-FUNDED RESEARCH PROGRAM AND TO HELPING MEMBERS OF THE LYMPHOMA COMMUNITY BY PROVIDING COMPREHENSIVE, DISEASE-SPECIFIC PROGRAMS AND SERVICES. LRF INVESTS MILLIONS OF DOLLARS EVERY YEAR TO COMBAT LYMPHOMA AND ASSIST THOSE WHOSE LIVES HAVE BEEN AFFECTED BY A LYMPHOMA DIAGNOSIS. LRF IS SUPPORTED BY MORE THAN 10,000 VOLUNTEERS WHO CONTRIBUTE THEIR TIME AND TALENTS TO FURTHER THE LRF MISSION AND SERVE THEIR LOCAL COMMUNITIES. LRF HAS EARNED THE TRUST OF INDIVIDUALS, PRIVATE FOUNDATIONS, PUBLIC COMPANIES, AND ORGANIZATIONS THAT FUND ITS WORK. BY DEMONSTRATING A HISTORY OF CAREFUL AND PROVEN FINANCIAL STEWARDSHIP. Form 990, Part III, line 4b RESEARCH: LRF REMAINS DEDICATED TO FINDING A CURE FOR LYMPHOMA THROUGH AN AGRESSIVELY-FUNDED RESEARCH PROGRAM. LRF SUPPORTS INNOVATIVE RESEARCH AND TRAINING FOR EARLY CAREER SCIENTISTS THROUGH ITS YOUNG INVESTIGATOR GRANTS-CLINICAL INVESTIGATOR CAREER DEVELOPMENT AWARDS, POSTDOCTORAL FELLOWSHIP GRANTS, AND THE LYMPHOMA CLINICAL RSEARCH MENTORING PROGRAM - AS WELL AS SUPPORTING RESEARCH IN KEY AREAS THROUGH DISEASE FOCUS AREA GRANTS FOR SENIOR SCIENTISTS. FOCUS AREA GRANTS HAVE IN THE PAST INCLUDED ADOLESCENT AND YOUNG ADULT LYMPHOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, FOLLICULAR LYMPHOMA, AND MANTLE CELL LYMPHOMA. THE RESEARCH PROGRAM ALSO ENCOMPASSES SCIENTIFIC WORKSHOPS AND SYMPOSIA ON SPECIAL TOPICS IN LYMPHOMA RESEARCH INCLUDING ORAL THERAPIES, IMMUNOTHERAPIES, AND SUBTYPE-SPECIFIC WORKSHOPS. LRF OFFERS A WIDE RANGE OF LYMPHOMA FOCUSED CONTINUING EDUCATION ACTIVITIES FOR NURSES, PHYSICIANS, AND SOCIAL WORKERS, SUCH AS WORKSHOPS, CONFERENCE SYMPOSIA, AND WEBCASTS. LRF'S Volunteer Scientific Advisory Board (SAB), comprised of 45 world-renowned Lymphoma experts, guides LRF's research activities, seeking out the most innovative and promising Lymphoma research projects for support. FORM 990, PART I, LINE 7B UNRELATED BUSINESS TAXABLE INCOME FROM FORM 990-T THE AMOUNT REPORTED ON PART I, LINE 7B INCLUDES CERTAIN FRINGE BENEFIT EXPENSES SUBJECT TO UNRELATED BUSINESS TAXABLE INCOME UNDER IRC SECTION 512(A)(7) AMOUNTS THAT ARE NOT CLASSIFIED AS REVENUE AND, THEREFORE, NOT REPORTED AS SUCH ON FORM 990, PART VIII. Form 990, Part VI, Section A, Line 2 Michael Werner and Robert Werner have a family relationship. Form 990, Part VI, Section B, Line 11b THE ORGANIZATION'S FORM 990 IS PREPARED INTERNALLY BY THE FINANCE DEPARTMENT AND IS REVIEWED BY MANAGEMENT BEFORE REVIEW BY THE ORGANIZATION'S INDEPENDENT ACCOUNTING FIRM. THE FORM 990 IS THEN REVIEWED BY THE AUDIT COMMITTEE AND THE BOARD FOR COMMENT. Form 990, Part VI, Section B, Line 12c LRF has a conflict of interest policy which requires board members, officers, and staff, to review and sign annually. During the FY18 financial audit, LRF's external auditors reviewed the board and officers' statements. No conflict of interests were reported for the fiscal period ending June 30, 2018. In 2014, LRF established a formal process for review and disposition of potential conflicts of interest in accordance with the provisions of the New York Non-Profit Revitalization Act of 2013. FORM 990, PART VI, SECTION B, LINE 15 THE ORGANIZATION SETS COMPENSATION IN A MANNER GIVING RISE TO A REBUTTABLE PRESUMPTION THAT THE COMPENSATION IS REASONABLE UNDER STANDARDS SET FORTH IN TREASURY REGULATIONS SECTION 53.4958-6. SALARIES OF THE SENIOR STAFF, INCLUDING THE CEO, ARE DETERMINED BASED UPON MARKET INFORMATION COMPARABLE TO THE POSITION IN OTHER NON-PROFIT ORGANIZATIONS. THE CEO'S COMPENSATION IS APPROVED BY THE INTEGRATION COUNCIL, WHICH HAS BEEN DULY AUTHORIZED BY THE BOARD AND CONSISTS OF INDEPENDENT MEMBERS, AND THE APPROVAL IS DOCUMENTED CONTEMPORANEOUSLY IN THE COUNCIL MINUTES. FORM 990, PART VI, SECTION C, LINE 19 FINANCIAL STATEMENTS ARE ON THE ORGANIZATION'S WEBSITE FOR VIEWING. SIGNED CONFLICT OF INTERESTS FORMS AND GOVERNING DOCUMENTS ARE KEPT ON FILE IN LRF'S MAIN OFFICE AND AVAILABLE FOR VIEW ON-SITE. LRF Research Inc Wall Street Plaza/88 Pine St Ste New York NY 10005 611844536 Investment NY Lymphoma Resear C 0 0 1.00000 true false false false false false false false false false false false false false true true false false false false LRF RESEARCH INC O 29668 Invoices paid